ClinicalTrials.gg
CompletedNCT01071954Updated Jan 18, 2020Results posted

A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

A Phase 3 interventional study of Romiplostim in Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP, sponsored by Amgen. Completed at 31 sites in 4 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by Amgen · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
13th of 29
66 · median 62
Started
2009
with 2 others
Phase 3
13 of 29
1 open now
Registered
12th of 29
by date
Lead sponsor
14 of 29
Amgen

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 13th largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 3, and was the 12th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

This is an extension study designed to assess the safety and durability of platelet count increases with romiplostim treatment of thrombocytopenic patients with immune (Idiopathic) thrombocytopenia purpura. This study is available to pediatric patients who have completed a previous romiplostim ITP study and meet the eligibility criteria of this study.

03

Conditions studied

  • Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP

Keywords

  • Immune thrombocytopenic Purpura
  • Pediatric
  • Thrombocytopenia
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject or subject's legally acceptable representative has provided .
  • Subject completed a romiplostim study for the treatment of thrombocytopenia in pediatric subjects with ITP.

Exclusion criteria

Exclusion Criteria:

  • Subject has or previously had any bone marrow stem cell disorder (any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled in the study).
  • Subject has any new active diagnosed since enrollment in the previous romiplostim ITP study.
  • Subject received any alkylating agents within four weeks before the screening visit or anticipated use during the time of the proposed study.
  • Other medications are excluded.
  • Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s) (with the exception of romiplostim in a previous clinical study).
  • Female subject of child bearing potential (defined as having first menses) is not willing to use highly effective during treatment and for 4 weeks after the end of treatment.
  • Female subject is pregnant or breast feeding, or planning to become pregnant within 4 weeks after the end of treatment.
  • Subject has known sensitivity to any of the products to be administered during dosing.
  • Subject previously has entered this study (this will depend on the type of study).
  • Subject will not be available for protocol required study visits, to the best of the subject and investigator's knowledge.
  • Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written and/or to comply with all required study procedures.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Romiplostim

    Participants received romiplostim administered by subcutaneous injection once a week. The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of between 50 x 10\^9/L and 200 x 10\^9/L.

    Biological: Romiplostim

Interventions

  • BiologicalRomiplostim

    Administered by subcutaneous injection once a week.

    Also known as: Nplate

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    The adverse event (AE) severity grading scale used was the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grading scale, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. A serious adverse event was defined as an adverse event that met at least one of the following serious criteria: * fatal * life threatening (places the subject at immediate risk of death) * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. The investigator assessed whether each adverse event was possibly related to the investigational product.

    Time frame: From first dose of study drug until 1 week after last dose. The median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).

  2. Duration Adjusted Rate of Treatment Emergent Adverse Events

    Exposure adjusted rate was defined as the total number of events divided by the duration of time participants were under observation. The adverse event (AE) severity grading scale used was the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grading scale, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. A serious adverse event was defined as an adverse event that met at least one of the following serious criteria: * fatal * life threatening (places the subject at immediate risk of death) * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. The investigator assessed whether each adverse event was possibly related to the study drug.

    Time frame: From first dose of study drug until 1 week after last dose. The median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).

  3. Number of Participants Who Developed Antibodies to Romiplostim

    Two validated assays were used to test for antibodies to romiplostim / the thrombopoietin-mimetic peptide component of romiplostim (TMP). The first was an immunoassay to confirm the presence of antibodies. The second was a cell-based bioassay to detect neutralizing or inhibitory effects in vitro. If a sample was positive in both assays, a participant was defined as positive for neutralizing antibodies. Transient antibodies are those positive post-baseline but negative at the last time point tested. Persistent antibodies were those positive at the last time point tested.

    Time frame: Once a year until the end of treatment and 1 week after the end of treatment; median (minimim, maximum) time on study was 34 (2, 91) months.

  4. Number of Participants Who Developed Antibodies to Endogenous Thrombopoietin

    Two validated assays were used to test for antibodies to endogenous thrombopoietin (TPO). The first was an immunoassay to confirm the presence of antibodies. The second was a cell-based bioassay to detect neutralizing or inhibitory effects in vitro. If a sample was positive in both assays, a participant was defined as positive for neutralizing antibodies. Transient antibodies are those positive post-baseline but negative at the last time point tested. Persistent antibodies were those positive at the last time point tested.

    Time frame: Once a year until the end of treatment and 1 week after the end of treatment; median (minimim, maximum) time on study was 34 (2, 91) months.

Secondary outcomes

  1. Percentage of Participants With a Platelet Response

    Platelet response was defined as at least one platelet count ≥ 50 x 10\^9/L in the absence of rescue medication during the study.

    Time frame: Assessed every 4 weeks for the duration of treatment; the median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).

  2. Percentage of Participants Who Used Concomitant ITP Therapy

    Time frame: From baseline to the end of treatment; the median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).

07

Results

Posted Jan 29, 2019

Participant flow

This study was conducted at 28 centers in Australia, Canada, Spain, and the United States. Participants were enrolled from 30 December 2009 until 19 February 2015.

Participant flow — Overall Study
MilestoneRomiplostim
Started66
Received treatment65
Completed39
Not completed27
Withdrew: Noncompliance4
Withdrew: Adverse event1
Withdrew: Withdrawal by subject11
Withdrew: Requirement for alternative therapy5
Withdrew: Administrative decision5
Withdrew: Protocol specified criteria1

Outcome measures

PrimaryNumber of Participants With Adverse Events

The adverse event (AE) severity grading scale used was the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grading scale, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. A serious adverse event was defined as an adverse event that met at least one of the following serious criteria: * fatal * life threatening (places the subject at immediate risk of death) * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. The investigator assessed whether each adverse event was possibly related to the investigational product.

Time frame:
From first dose of study drug until 1 week after last dose. The median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsRomiplostim
All adverse events (AEs)64
Serious adverse events19
AEs leading to discontinuation of study drug2
AEs leading to withdrawal from study1
Grade 3 adverse events21
Grade 4 adverse events5
Grade 5 adverse events0
Treatment-related adverse events (TRAEs)17
Treatment-related serious adverse events1
TRAEs leading to discontinuation of study drug0
TRAEs leading to withdrawal from study0
Grade 3 treatment-related adverse events3
Grade 4 treatment-related adverse events1
Grade 5 treatment-related adverse events0
PrimaryDuration Adjusted Rate of Treatment Emergent Adverse Events

Exposure adjusted rate was defined as the total number of events divided by the duration of time participants were under observation. The adverse event (AE) severity grading scale used was the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grading scale, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. A serious adverse event was defined as an adverse event that met at least one of the following serious criteria: * fatal * life threatening (places the subject at immediate risk of death) * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. The investigator assessed whether each adverse event was possibly related to the study drug.

Time frame:
From first dose of study drug until 1 week after last dose. The median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).
Reported as:
Number · events per 100 subject-years
Duration Adjusted Rate of Treatment Emergent Adverse Events
events per 100 subject-yearsRomiplostim
All adverse events (AEs)1397.2
Serious adverse events29.7
AEs leading to discontinuation of study drug2.8
AEs leading to withdrawal from study0.6
Grade 3 adverse events38.5
Grade 4 adverse events6.6
Grade 5 adverse events0.0
Treatment-related adverse events (TRAEs)24.2
Serious treatment-related adverse events1.7
TRAEs leading to discontinuation of study drug0.0
TRAEs leading to withdrawal from study0.0
Grade 3 treatment-related adverse events2.8
Grade 4 treatment-related adverse events0.6
Grade 5 treatment-related adverse events0.0
PrimaryNumber of Participants Who Developed Antibodies to Romiplostim

Two validated assays were used to test for antibodies to romiplostim / the thrombopoietin-mimetic peptide component of romiplostim (TMP). The first was an immunoassay to confirm the presence of antibodies. The second was a cell-based bioassay to detect neutralizing or inhibitory effects in vitro. If a sample was positive in both assays, a participant was defined as positive for neutralizing antibodies. Transient antibodies are those positive post-baseline but negative at the last time point tested. Persistent antibodies were those positive at the last time point tested.

Time frame:
Once a year until the end of treatment and 1 week after the end of treatment; median (minimim, maximum) time on study was 34 (2, 91) months.
Reported as:
Count of participants · Participants
Number of Participants Who Developed Antibodies to Romiplostim
ParticipantsRomiplostim
Binding antibodies to romiplostim5
Transient binding antibodies to romiplostim4
Persistent binding antibodies to romiplostim1
Neutralizing antibodies to romiplostim1
Transient neutralizing antibodies to romiplostim0
Persistent neutralizing antibodies to romiplostim1
PrimaryNumber of Participants Who Developed Antibodies to Endogenous Thrombopoietin

Two validated assays were used to test for antibodies to endogenous thrombopoietin (TPO). The first was an immunoassay to confirm the presence of antibodies. The second was a cell-based bioassay to detect neutralizing or inhibitory effects in vitro. If a sample was positive in both assays, a participant was defined as positive for neutralizing antibodies. Transient antibodies are those positive post-baseline but negative at the last time point tested. Persistent antibodies were those positive at the last time point tested.

Time frame:
Once a year until the end of treatment and 1 week after the end of treatment; median (minimim, maximum) time on study was 34 (2, 91) months.
Reported as:
Count of participants · Participants
Number of Participants Who Developed Antibodies to Endogenous Thrombopoietin
ParticipantsRomiplostim
Binding antibodies to TPO2
Transient binding antibodies to TPO2
Persistent binding antibodies to TPO0
Neutralizing antibodies to TPO0
Transient neutralizing antibodies to TPO0
Persistent neutralizing antibodies to TPO0
SecondaryPercentage of Participants With a Platelet Response

Platelet response was defined as at least one platelet count ≥ 50 x 10\^9/L in the absence of rescue medication during the study.

Time frame:
Assessed every 4 weeks for the duration of treatment; the median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).
Reported as:
Number · percentage of participants
Percentage of Participants With a Platelet Response
percentage of participantsRomiplostim
Percentage of Participants With a Platelet Response93.8 ± 85.0
SecondaryPercentage of Participants Who Used Concomitant ITP Therapy
Time frame:
From baseline to the end of treatment; the median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).
Reported as:
Number · percentage of participants
Percentage of Participants Who Used Concomitant ITP Therapy
percentage of participantsRomiplostim
Percentage of Participants Who Used Concomitant ITP Therapy47.7 ± 35.1

Adverse events

Collected over From first dose of study drug until 1 week after last dose. The median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Romiplostim0/65 (0%)19/65 (29.2%)64/65 (98.5%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventRomiplostim
ThrombocytopeniaBlood and lymphatic system disorders4/65
PyrexiaGeneral disorders3/65
VomitingGastrointestinal disorders2/65
HeadacheNervous system disorders2/65
EpistaxisRespiratory, thoracic and mediastinal disorders2/65
AnaemiaBlood and lymphatic system disorders1/65
Febrile neutropeniaBlood and lymphatic system disorders1/65
Immune thrombocytopenic purpuraBlood and lymphatic system disorders1/65
LeukopeniaBlood and lymphatic system disorders1/65
Mouth haemorrhageGastrointestinal disorders1/65
Most frequent other events
Showing 10 of 69
Most frequent other events
EventRomiplostim
HeadacheNervous system disorders38/65
VomitingGastrointestinal disorders32/65
Upper respiratory tract infectionInfections and infestations32/65
ContusionInjury, poisoning and procedural complications32/65
EpistaxisRespiratory, thoracic and mediastinal disorders31/65
CoughRespiratory, thoracic and mediastinal disorders30/65
Oropharyngeal painRespiratory, thoracic and mediastinal disorders30/65
PyrexiaGeneral disorders28/65
NauseaGastrointestinal disorders24/65
NasopharyngitisInfections and infestations22/65

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall Study
Mean10.3 ± 4.2
Age, Customized
Age, Customized(Participants)Overall Study
Children (2-11 years)37
Adolescents (12-17 years)28
Adults (18-64 years)1
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female37
Male29
Race
Race(Participants)Overall Study
White or Caucasian40
Black or African American9
Hispanic or Latino9
Asian6
Japanese0
American Indian or Alaska Native0
Native Hawaiian or Other Pacific Islander0
Aborigine0
Other2
08

Study locations

31 sites
  • Research Site
    Orange, California 92868, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    Washington, District of Columbia 20010, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Peoria, Illinois 61615, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    New Orleans, Louisiana 70118, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Kansas City, Missouri 64108, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Las Vegas, Nevada 89109, United States
  • Research Site
    New Brunswick, New Jersey 08901, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Cincinnati, Ohio 45229, United States
  • Research Site
    Columbus, Ohio 43205, United States
  • Research Site
    Pittsburgh, Pennsylvania 15224, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Dallas, Texas 75390, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Randwick, New South Wales 2031, Australia
  • Research Site
    South Brisbane, Queensland 4101, Australia
  • Research Site
    Parkville, Victoria 3052, Australia
  • Research Site
    Toronto, Ontario M5G 1X8, Canada
  • Research Site
    Montreal, Quebec H3T 1C5, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Barcelona, Cataluña 08035, Spain
09

References and documents

Publications

  • Tarantino MD, Bussel JB, Blanchette VS, Beam D, Roy J, Despotovic J, Raj A, Carpenter N, Mehta B, Eisen M. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. Haematologica. 2019 Nov;104(11):2283-2291. doi: 10.3324/haematol.2018.202283. Epub 2019 Mar 7. PubMed 30846500 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2009 to primary completion in Jan 2017, 84 months.

Results were first posted in Jan 2019, 2 years after primary completion. A results delay was requested in Jul 2017.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 84 months is above that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2009
First posted
Feb 19, 2010
StartActual
Dec 30, 2009
Primary completionActual
Jan 12, 2017
CompletionActual
Jan 12, 2017
Results delay requested
Jul 27, 2017
Results first posted
Jan 29, 2019
Last update
Jan 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01071954
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 19, 2010
Start date
Dec 30, 2009
Primary completion
Jan 12, 2017
Completion
Jan 12, 2017
Results posted
Jan 29, 2019
Last update
Jan 18, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion